PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.20% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-02-22
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-09-30 was 4.30%, a 48.28% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-06-30 was 3.60%, a 24.14% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 4.30%, a 126.32% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-09-30 was 2.90%, a 222.22% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.20%, a 90.91% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.20%, a 120.00% increase from fiscal 2021.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 1.00%, a 11.11% increase from fiscal 2020.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.90%, a 60.87% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2023-12-31 | 4.20% 10-K · filed 2024-02-22 | |||
| 2023-09-30 | 4.30% 10-Q · filed 2023-11-02 | 4.20% 10-Q · filed 2023-11-02 | ||
| 2023-06-30 | 3.60% 10-Q · filed 2023-08-03 | 4.20% 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | 4.30% 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | 2.20% 10-K · filed 2024-02-22 | |||
| 2022-09-30 | 2.90% 10-Q · filed 2023-11-02 | 2.10% 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | 2.90% 10-Q · filed 2023-08-03 | 2.00% 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | 1.90% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 1.00% 10-K · filed 2024-02-22 | |||
| 2021-09-30 | 0.90% 10-Q · filed 2022-11-03 | 1.00% 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-08 | 1.00% 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | 1.00% 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 0.90% 10-K · filed 2023-02-28 | |||
| 2020-09-30 | 0.30% 10-Q · filed 2021-11-04 | 1.00% 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | 0.40% 10-Q · filed 2021-08-05 | 1.10% 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | 1.20% 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | 2.30% 10-K · filed 2022-02-25 | |||
| 2019-09-30 | 1.80% 10-Q · filed 2020-11-04 | 2.30% 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | 2.20% 10-Q · filed 2020-08-06 | 2.50% 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | 2.50% 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | 2.80% 10-K · filed 2021-02-26 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-05 | 2.80% 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | 2.80% 10-Q · filed 2019-08-06 | 2.80% 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | 2.80% 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | 2.00% 10-K · filed 2020-03-03 | |||
| 2017-09-30 | 2.00% 10-Q · filed 2018-11-06 | 2.00% 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | 2.00% 10-Q · filed 2018-08-07 | 2.00% 10-Q · filed 2018-08-07 | ||
| 2016-12-31 | 1.50% 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |